Treatment Outcomes of Primary vs. Referred Patients with Multiple Myeloma Receiving Talquetamab or Teclistamab

被引：0
|
作者：
Fries, Gina [1 ]
Alshlah, Ali [1 ]
Baran, Andrea [1 ]
Lipe, Brea [2 ]
机构：
[1] Univ Rochester, Med Ctr, Rochester, NY USA
[2] UR Med, Dept Med, Rochester, NY USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-119
引用
收藏
页码：S110 / S110
页数：1
相关论文
共 50 条
  • [41] Survival in patients with multiple primary melanomas vs. single primary melanoma
    Rowe, C.
    Law, M.
    Palmer, J.
    MacGregor, S.
    Hayward, N.
    Khosrotehrani, K.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2016, 57 : 4 - 4
  • [42] Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed/refractory multiple myeloma
    Reece, Donna
    Diels, Joris
    Van Sanden, Suzy
    Pei, Lixia
    Ammann, Eric
    Heuck, Christoph
    Kane, Colleen
    Londhe, Anil
    Peterson, Steve
    Chari, Ajai
    CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 (10) : 1769 - 1783
  • [43] Treatment Patterns and Outcomes in Elderly Patients with Multiple Myeloma
    Bang, Soo-Mee
    Kyle, Robert A.
    Lee, Jae Hoon
    Dispenzieri, Angela
    Larson, Dirk
    Colby, Colin L.
    Rajkumar, S. Vincent
    Kumar, Shaji
    BLOOD, 2011, 118 (21) : 1703 - 1703
  • [44] Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab
    Naqvi, Syed
    Shrestha, Asis
    Alzubi, Marah
    Alrawabdeh, Jawad
    Thanendrarajan, Sharmilan
    Zangari, Maurizio
    van Rhee, Frits
    Schinke, Carolina
    Al Hadidi, Samer
    EJHAEM, 2024, 5 (04): : 789 - 792
  • [45] Treatment patterns and outcomes in elderly patients with multiple myeloma
    S-M Bang
    R A Kyle
    S V Rajkumar
    S Kumar
    Leukemia, 2013, 27 : 971 - 974
  • [46] Treatment patterns and outcomes in elderly patients with multiple myeloma
    Bang, S-M
    Kyle, R. A.
    Rajkumar, S. V.
    Kumar, S.
    LEUKEMIA, 2013, 27 (04) : 971 - 974
  • [47] Real World Evaluation of Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM)
    Maringanti, Sireesha Asoori
    Lin, Yi
    Estritis, Stathis
    Martinez-Lopez, Joaquin
    Bansal, Radhika
    Fotiou, Despina
    Corona, Magdalena
    Chhabra, Saurabh
    Brunaldi, Larissa
    Corraes, Andre De Menezes Silva
    Parrondo, Ricardo
    Kapoor, Prashant
    Ailawadhi, Sikander
    Mas, Reyes
    Tamayo, Andrea
    Dimopoulos, Meletios
    Durie, Brian
    Martin, Thomas
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S506 - S507
  • [48] Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma
    Davis, James A.
    Snyder, Jordan
    Rice, Mikhaila
    Moore, Donald C.
    Cahoon, Christopher
    Julian, Kelley
    Wagner, Charlotte B.
    Granger, Katelynn
    Green, Kimberly M.
    Atrash, Shebli
    Hill, Hailey
    Mcelwee, Jessica
    Elsey, Grace
    Khouri, Jack
    Rudoni, Joslyn
    Mahmoudjafari, Zahra
    Nachar, Victoria R.
    BLOOD CANCER JOURNAL, 2025, 15 (01):
  • [49] Assessment and monitoring of patients receiving chemotherapy for multiple myeloma: strategies to improve outcomes
    Faiman, Beth
    Valent, Jason
    BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2016, 6 : 21 - 35
  • [50] Greater benefits for patients receiving sustained vs. interrupted treatment with galantamine
    Aronson, SM
    VanBaelen, B
    Kershaw, P
    NEUROBIOLOGY OF AGING, 2004, 25 : S310 - S311
12345